News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)

April 24, 2024

April 24, 2024

The Nomination Committee’s of Egetis Therapeutics AB (publ) (“Egetis”) proposals for the annual general meeting on May 6, 2024 were published on March 29, 2024 in connection with the notice to the annual general meeting. After publication of the notice, the Nomination Committee has been informed by the Chairman of the Board Thomas Lönngren that he wishes to decline re-election as Chairman of the Board but is available for election as a Board member. Furthermore, the current Board member Elisabeth Svanberg has announced that she is available for re-election (previously declined). Against this background, the Nomination Committee has therefore decided to adjust its proposal for the number of Board members as well as the election of Board members and Chairman of the Board by proposing that the Board is increased by one Board member to a total of six members, that all current Board members are re-elected and that Mats Blom is elected as new Chairman of the Board.

Consequently, the Nomination Committee’s adjusted proposals entail that the number of Board members is proposed to be six without deputy members (unchanged from last year) and that Thomas Lönngren, Mats Blom, Gunilla Osswald, Behshad Sheldon, Elisabeth Svanberg and Peder Walberg shall be re-elected as Board members (unchanged from last year). Mats Blom is proposed as new Chairman of the Board and thereby replaces the current Chairman of the Board Thomas Lönngren.

As a result of the proposed increase of the number of Board members, the total remuneration for the Board will increase with an additional fee for one Board member. This results in the total proposed remuneration to the Board being unchanged compared to the total current remuneration to the Board adopted by the annual general meeting in 2023.

The Nomination Committee’s proposals to the annual general meeting 2024 remain otherwise unchanged.

The annual general meeting 2024 of Egetis will be held in Stockholm on May 6, 2024.
For further information, please contact:

Peder Walberg,



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10